Roland Otto Buhl

Q: What Schools Are Affiliated With Roland Otto Buhl

Roland Otto Buhl is affiliated with the following schools: University of Mainz, Vrije Universiteit Brussel

Roland Otto Buhl's AcademicInfluence.com Rankings

Roland Otto Buhl

Philosophy

#7340

World Rank

#10536

Historical Rank

Logic

#4399

World Rank

#5683

Historical Rank

philosophy Degrees

Roland Otto Buhl

Biology

#9962

World Rank

#13235

Historical Rank

Immunology

#612

World Rank

#632

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Roland Otto Buhl's Degrees

Doctorate Medicine Stanford University

Why Is Roland Otto Buhl Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roland Otto Buhl's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial (2012) (1435)
High-dose acetylcysteine in idiopathic pulmonary fibrosis. (2005) (936)
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. (2001) (797)
SYSTEMIC GLUTATHIONE DEFICIENCY IN SYMPTOM-FREE HIV-SEROPOSITIVE INDIVIDUALS (1989) (646)
The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma (2005) (399)
Systemic deficiency of glutathione in cystic fibrosis. (1993) (390)
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) (2015) (341)
Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases (2014) (327)
Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD (2010) (297)
Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? (2002) (281)
Revisiting Type 2‐high and Type 2‐low airway inflammation in asthma: current knowledge and therapeutic implications (2017) (272)
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. (2015) (254)
Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. (2003) (252)
GINA 2019: a fundamental change in asthma management (2019) (244)
Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations (2007) (244)
Overall asthma control: the relationship between current control and future risk. (2010) (239)
Safety and tolerability of omalizumab (2009) (231)
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. (2001) (214)
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. (2001) (208)
The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. (1994) (197)
Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis (1991) (192)
Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. (2003) (182)
MACVIA‐ARIA Sentinel NetworK for allergic rhinitis (MASK‐rhinitis): the new generation guideline implementation (2015) (178)
Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma (2019) (166)
Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. (2012) (163)
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma (2002) (163)
Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. (2000) (159)
Integrated care pathways for airway diseases (AIRWAYS-ICPs) (2014) (155)
Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency (2013) (155)
Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature (2018) (154)
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD (2010) (152)
Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. (2003) (147)
Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. (2007) (143)
Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. (1991) (139)
Omalizumab and the risk of malignancy: results from a pooled analysis. (2012) (136)
Severe eosinophilic asthma: a roadmap to consensus (2017) (134)
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations (2010) (133)
Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis (2008) (132)
IL-22 Is Produced by Innate Lymphoid Cells and Limits Inflammation in Allergic Airway Disease (2011) (131)
Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. (1991) (128)
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes (2021) (126)
Oral supplementation with whey proteins increases plasma glutathione levels of HIV‐infected patients (2001) (126)
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle (2016) (124)
Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. (2009) (122)
The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. (2009) (119)
Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma (2006) (119)
Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. (2010) (118)
Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. (1999) (116)
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease (2010) (113)
Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. (1995) (112)
Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis (2002) (109)
Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. (1990) (109)
[Guidelines for diagnosis and treatment of asthma patients]. (2006) (104)
Effects of long-term supplementation with whey proteins on plasma glutathione levels of HIV-infected patients (2002) (98)
Inhibition of cAMP Degradation Improves Regulatory T Cell-Mediated Suppression1 (2009) (98)
Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (96)
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma (2002) (96)
Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. (2018) (95)
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study (2007) (95)
Activation of alveolar macrophages in asymptomatic HIV-infected individuals. (1993) (91)
Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. (2003) (89)
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (2019) (87)
Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. (2015) (87)
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial. (2016) (87)
Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. (2006) (82)
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes (2021) (82)
MDCT assessment of airway wall thickness in COPD patients using a new method: correlations with pulmonary function tests (2008) (82)
A single nasal allergen challenge increases induced sputum inflammatory markers in non‐asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin‐5 (2003) (81)
Measuring asthma control: a comparison of three classification systems (2010) (81)
Mast cell-derived tumour necrosis factor is essential for allergic airway disease (2008) (80)
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma (2019) (80)
Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. (2002) (78)
Care pathways for the selection of a biologic in severe asthma (2017) (77)
Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. (2010) (76)
Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? (2013) (76)
Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. (2003) (76)
Kalanchoe pinnata inhibits mast cell activation and prevents allergic airway disease. (2012) (73)
c‐erbB‐2 Expression in small‐cell lung cancer is associated with poor prognosis (2001) (73)
Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. (2010) (71)
Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial (2009) (69)
The 'real-life' COPD patient in Germany: The DACCORD study. (2016) (66)
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases (2019) (65)
[Guideline for the Diagnosis and Treatment of COPD Patients - Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology]. (2018) (65)
Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. (1996) (64)
Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. (1996) (64)
Soluble Triggering Receptor Expressed on Myeloid Cells 1 Is Released in Patients with Stable Chronic Obstructive Pulmonary Disease (2007) (63)
Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. (1990) (60)
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps (2011) (60)
Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. (1993) (59)
Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. (2006) (59)
Against all odds: anti-IgE for intrinsic asthma? (2013) (58)
Lung transplantation: a treatment option in end-stage lung disease. (2014) (58)
Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score. (2017) (57)
Glutathione in induced sputum of healthy individuals and patients with asthma (2001) (57)
Increased glutathione disulfide and nitrosothiols in sputum supernatant of patients with stable COPD. (2004) (56)
“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD (2017) (56)
Effect of internal thoracic artery preparation on blood loss, lung function, and pain. (1999) (55)
Fluticasone/Formoterol Combination Therapy versus Budesonide/Formoterol for the Treatment of Asthma: A Randomized, Controlled, Non-Inferiority Trial of Efficacy and Safety (2012) (55)
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. (2014) (55)
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020) (2020) (55)
Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. (2015) (54)
Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis (2015) (54)
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD (2012) (53)
Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. (2011) (53)
Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge (2020) (50)
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (2016) (49)
Anti-IgE antibodies for the treatment of asthma (2005) (48)
Improvement in quality of life with omalizumab in patients with severe allergic asthma (2006) (48)
Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study (2015) (47)
Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany (2012) (47)
New horizons in early stage COPD--improving knowledge, detection and treatment. (2011) (46)
Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. (1993) (46)
Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. (2004) (46)
The Wnt/β-Catenin Pathway Attenuates Experimental Allergic Airway Disease (2014) (45)
Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. (2001) (44)
Monitoring free serum IgE in severe asthma patients treated with omalizumab. (2012) (44)
[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]. (2017) (43)
Newly Diagnosed Chronic Obstructive Pulmonary Disease (2003) (42)
[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]. (2008) (42)
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies (2020) (42)
TLR3 but Not TLR7/8 Ligand Induces Allergic Sensitization to Inhaled Allergen (2012) (42)
Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. (2021) (41)
Idiopathic Pulmonary Fibrosis: Current Clinical Concepts and Challenges in Management (1994) (41)
ARIA guideline 2019: treatment of allergic rhinitis in the German health system (2019) (41)
The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing (2004) (40)
Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha 1-protease inhibitor caused by different forms of oxidative stress. (1997) (40)
Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. (2003) (38)
Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. (2019) (38)
European Respiratory Society guidelines for the diagnosis of asthma in adults (2022) (37)
Effect of different asthma treatments on risk of cold-related exacerbations (2011) (37)
Anticholinergics in the Treatment of Chronic Obstructive Pulmonary Disease (2002) (37)
[German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. (2013) (36)
Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. (2003) (35)
CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. (2012) (35)
Quality of Life in NSCLC Survivors — A Multicenter Cross‐Sectional Study (2019) (35)
The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy (2012) (35)
Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. (2008) (34)
Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes. (2021) (34)
c-kit Expression in Adenocarcinomas of the Lung (2004) (34)
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice (2020) (34)
Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. (2005) (33)
A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study. (2017) (32)
Measurement of exhaled nitric oxide: Comparison of different analysers (2010) (32)
GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study. (2017) (32)
Regulatory T Cells More Effectively Suppress Th1-Induced Airway Inflammation Compared with Th2 (2011) (31)
Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes. (2021) (31)
Mast Cells Induce Migration of Dendritic Cells in a Murine Model of Acute Allergic Airway Disease (2009) (31)
Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. (1993) (30)
Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. (2017) (30)
Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis. (2004) (29)
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study (2018) (28)
A year in the life of German patients with COPD: the DACCORD observational study (2016) (27)
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. (2019) (27)
Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. (2003) (27)
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic (2020) (27)
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. (2007) (27)
Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma (2008) (26)
Tumor necrosis factor-alpha modulates the selective interference of hypnotics and sedatives to suppress N-formyl-methionyl-leucyl-phenylalanine-induced oxidative burst formation in neutrophils. (1997) (26)
Lung allocation score: the Eurotransplant model versus the revised US model – a cross‐sectional study (2018) (25)
Erratum: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics (European Respiratory Journal (2001) vol. 18 (254-261)) (2001) (25)
Soot-Exposed Mononuclear Cells Increase Inflammatory Cytokine mRNA Expression and Protein Secretion in Cocultured Bronchial Epithelial Cells (2000) (25)
Induced sputum cell profiles in lung transplant recipients with or without chronic rejection: correlation with lung function (2001) (25)
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy (2010) (25)
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies (2017) (24)
ARIA guideline 2019: treatment of allergic rhinitis in the German health system. (2019) (24)
SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. (2003) (24)
Imbalance between oxidants and antioxidants in the lungs of HIV-seropositive individuals. (1994) (23)
Indoor Air Pollutants Stimulate Interleukin-8-Specific mRNA Expression and Protein Secretion of Alveolar Macrophages (1999) (22)
Increased concentrations of glutathione in induced sputum of patients with mild or moderate allergic asthma. (2004) (22)
Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. (2012) (22)
Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis patients. (1999) (22)
Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA (2020) (21)
Detection of normal mediastinal lymph nodes by ultrasonography (1997) (20)
Comparing asthma treatment in elderly versus younger patients. (2011) (20)
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy (2017) (20)
Glutathione deficiency and HIV (1990) (20)
Coincident airway exposure to low-potency allergen and cytomegalovirus sensitizes for allergic airway disease by viral activation of migratory dendritic cells (2019) (19)
Future directions in the pharmacologic therapy of chronic obstructive pulmonary disease. (2005) (19)
Induced sputum methodology: Validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. (2004) (19)
Psychological distress in lung cancer survivors at least 1 year after diagnosis—Results of a German multicenter cross‐sectional study (2018) (19)
The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods (2015) (19)
TA-MUC1 epitope in non-small cell lung cancer. (2009) (18)
Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma (2020) (18)
Controlled and uncontrolled allergic asthma in routine respiratory specialist care – a clinical–epidemiological study in Germany (2011) (18)
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. (2018) (18)
One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. (2019) (18)
[Recommendations for the choice of inhalatory systems for drug prescription]. (2001) (18)
Sputum induction leads to a decrease of exhaled nitric oxide unrelated to airflow (2003) (18)
Do barbiturates and their solutions suppress FMLP-induced neutrophil chemiluminescence? (1994) (18)
Measurement of Fractional Exhaled Nitric Oxide: Comparison of Three Different Analysers (2019) (17)
Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma. (2018) (17)
Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort (2020) (17)
Intermediate-term clinical and hemodynamic results of the neonatal arterial switch operation for complete transposition of the great arteries. (1992) (17)
Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. (1997) (17)
GARP inhibits allergic airway inflammation in a humanized mouse model (2016) (17)
Opioids with different affinity for subreceptors induce different effects on early and late sensory evoked potentials (SEP) in man. (1986) (16)
Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. (2008) (16)
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age (2016) (16)
Monitoring free serum IgE in severe asthma patients treated with omalizumab (2011) (16)
Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials (2020) (16)
Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma (2007) (16)
&bgr;‐Blockers in COPD: A Cohort Study From the TONADO Research Program (2018) (16)
The Canonical but Not the Noncanonical Wnt Pathway Inhibits the Development of Allergic Airway Disease (2018) (16)
The Prognostic Impact of Blood Group-Related Antigen Lewis Y and the ABH Blood Groups in Resected Non-Small Cell Lung Cancer (2008) (16)
Levels of Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease (2011) (16)
Assessing biomarkers in a real-world severe asthma study (ARIETTA). (2016) (16)
Eligibility for treatment with omalizumab in Italy and Germany. (2014) (15)
Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma. (2004) (15)
Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE). (2015) (15)
Omalizumab versus ‘Usual Care’: Results from a Naturalistic Longitudinal Study in Routine Care (2012) (15)
Long-term treatment of α 1-antitrypsin deficiency-related pulmonary emphysema with human α 1-antitrypsin (2002) (15)
β-Blockers in COPD (2018) (14)
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. (2021) (14)
Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. (2015) (14)
Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort. (2020) (14)
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma (2019) (14)
Additional NO2 exposure induces a decrease in cytokine specific mRNA expression and cytokine release of particle and fibre exposed human alveolar macrophages. (1999) (14)
Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. (2013) (14)
Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients. (2017) (13)
Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study (2016) (13)
Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting (2019) (13)
Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. (2018) (13)
Stability of Glutathione in Induced Sputum: Impact of Freezing (2003) (13)
The Treatment of Mild and Moderate Asthma in Adults. (2020) (13)
Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer (2018) (12)
Effects of Piclamilast, a Selective Phosphodiesterase-4 Inhibitor, on Oxidative Burst of Sputum Cells From Mild Asthmatics and Stable COPD Patients (2004) (12)
Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease (2017) (12)
Lymphocyte transformation test in a group of foundry workers exposed to beryllium and non-exposed controls. (1986) (12)
Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma. (2020) (12)
Economic evaluation of BDP/formoterol fixed vs two single inhalers in asthma treatment (2010) (12)
The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort (2019) (12)
Dysfunctional inhibitory muscarinic receptors mediate enhanced histamine release in isolated human bronchi. (2007) (12)
Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions. (2005) (12)
[Treatment of bronchial asthma using a new adjustable combination treatment plan: Asthma Control Plan (ATACO)]. (2001) (12)
[Guidelines for the diagnosis and treatment chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für pneumologie]. (2002) (12)
[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]. (2017) (11)
Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma (2012) (11)
Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. (2019) (11)
Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials. (2015) (11)
Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis (2016) (11)
Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On The Path to Personalized Medicine. (2020) (11)
Patients' perceptions of well‐being using a guided self‐management plan in asthma (2004) (10)
Disease-modifying anti-asthmatic drugs (2022) (10)
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (2020) (10)
Budesonide/formoterol for the treatment of asthma (2003) (10)
Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials (2020) (10)
Future perspectives of anticholinergics for the treatment of asthma in adults and children (2019) (10)
Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study. (2012) (10)
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma]. (2008) (10)
Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. (2021) (10)
[Seasonal variations of serum-IgE and potential impact on dose-calculation of omalizumab (rhuMab-E25, anti-IgE)]. (2004) (10)
Dissimilarity between Seasonal Changes in Airway Responsiveness to Adenosine-5’-Monophosphate and Methacholine in Patients with Grass Pollen Allergic Rhinitis: Relation to Induced Sputum (2003) (9)
QVA 149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease (9)
Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET (2020) (9)
[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]. (2017) (9)
Modulation of cystic fibrosis transmembrane conductance regulator gene - expression by elevation of intracellular cyclic AMP. (1998) (9)
[Guideline for the Diagnosis and Treatment of Asthma - Addendum 2020 - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]. (2021) (9)
[Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin]. (1998) (9)
A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. (2020) (9)
[Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)]. (2020) (8)
In vivo assessment of pulmonary oxidant damage: the role of bronchoalveolar lavage. (1994) (8)
Do barbiturates impair zymosan-induced granulocyte function? (1994) (8)
Spirometric gated quantitative computed tomography of the lung in healthy smokers and nonsmokers. (1997) (8)
Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. (2011) (8)
Single and Synergistic Effects of Type 2 Cytokines on Eosinophils and Asthma Hallmarks (2019) (8)
[The German severe asthma registry]. (2012) (8)
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy (2007) (7)
[Combination of asthma and COPD: more frequent as considered to be?]. (2006) (7)
THE RECOVERY-ELISA—A NOVEL ASSAY TECHNIQUE TO MONITOR THERAPY WITH HUMANIZED ANTIBODIES: THE EXAMPLE OF OMALIZUMAB (2013) (7)
Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies (2020) (7)
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies (2015) (7)
Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion (2019) (7)
Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5. (2019) (7)
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months (2021) (7)
Returning to work in lung cancer survivors—a multi-center cross-sectional study in Germany (2020) (7)
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management (2020) (7)
Fraction of exhaled nitric oxide is associated with disease burden in the German Asthma Net severe asthma cohort (2022) (6)
Studienendpunkte bei der chronisch-obstruktiven lungenerkrankung (COPD): "Minimal clinically important difference" (2008) (6)
Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies (2018) (6)
Impact of donor lung quality on post‐transplant recipient outcome in the Lung Allocation Score era in Eurotransplant – a historical prospective study (2020) (6)
Use of psychosocial services by lung cancer survivors in Germany (2019) (6)
Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET (2022) (6)
Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[(18)F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([(18)F]FEFE) for the in vivo visualisation and quantification of the beta2-adrenergic receptor status in lung. (2003) (6)
Disease-Modifikation und Dauer einer Omalizumab-Therapie bei Patienten mit schwerem allergischen Asthma (2014) (6)
The value of preoperative chest X-rays in gynecological patients (2004) (6)
[Lung compliance in man is impaired by the rapid injection of alfentanyl]. (1986) (6)
Two pathways, one patient; UK asthma guidelines (2018) (6)
The whole story: treatment outcomes with Symbicort. (2002) (6)
Tiotropium Respimat® Add-On To Inhaled Corticosteroids Improves Lung Function In Patients With Symptomatic Mild Asthma: Results From A Phase III Trial (2014) (6)
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology (2018) (5)
Overall response to anti-IL5/anti-IL5Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness. (2022) (5)
Somatosensory-evoked potentials (SEPs) are affected differently by mu- and kappa-selective opioids in the dog. (1987) (5)
Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies (2015) (5)
Once-daily Symbicort (budesonide/eformoterol In A Single Inhaler) Is Effective In Moderate-persistent Asthma (2001) (5)
Indacaterol Once-Daily Reduces COPD Exacerbations over 52 Weeks of Treatment. (2009) (5)
Therapiestrategien bei Asthma (2012) (5)
Roflumilast for asthma: Weighing the evidence. (2015) (5)
[Therapy of lung diseases with anti-oxidants]. (1994) (5)
Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma (2020) (5)
Sputum Levels of Reduced Glutathione Increase 24 Hours after Allergen Challenge in Isolated Early, but Not Dual Asthmatic Responders (2004) (5)
Eosinophilic and Noneosinophilic Asthma (2021) (4)
[Specific immunotherapy for allergic asthma?]. (2003) (4)
Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat in Patients With Chronic Obstructive Pulmonary Disease: Two 1-Year Studies (2014) (4)
Asbestos-exposed blood monocytes--deoxyribonucleic acid strand lesions in co-cultured bronchial epithelial cells. (2000) (4)
[Bronchial asthma versus chronic obstructive lung disease (COPD). From pathogenesis to differential diagnosis and differential therapy]. (2005) (4)
Pooled Safety Analysis Of Adjudicated Serious Adverse Events With The Fixed-Dose Combination Of Tiotropium + Olodaterol (2016) (4)
Indacaterol Provides Effective Bronchodilation In Patients With Chronic Obstructive Pulmonary Disease Irrespective Of Patient Age (<65 Or e65 Years) (2010) (4)
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (2017) (4)
Is the patient’s baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen? (2011) (4)
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. (2023) (4)
[Therapy of lung diseases with antiproteases]. (1994) (4)
Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lung (2018) (4)
Differences of airway dimensions between patients with and without bronchiolitis obliterans syndrome after lung transplantation-Computer-assisted quantification of computed tomography. (2016) (4)
Response to mepolizumab treatment is sustained across 4-weekly dosing periods (2020) (4)
P296 Effect of tiotropium/olodaterol therapy on copd exacerbations in the tonado® studies (2016) (4)
P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold b (2016) (4)
Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations (2022) (4)
Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment (2020) (4)
Workflow-centred open-source fully automated lung volumetry in chest CT. (2019) (3)
Platinum-Based, Leukocyte-Depleting Chemotherapy Does Not Alter Induced Sputum Markers of Neutrophilic Inflammation in COPD Patients with Unresectable Non-Small Cell Lung Cancer (2003) (3)
Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app. (2022) (3)
Effect of histamine and adenosine 5'-monophosphate provocation on sputum neutrophils and related mediators in atopic patients. (2005) (3)
Predictors Of Asthma Control And A Risk Score For Exacerbations (2012) (3)
Inhaled steroids and prevalence of osteoporosis in chronic obstructive pulmonary disease: Data from the DACCORD cohort (2020) (3)
Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab (2022) (3)
Demonstration of pulmonary β2-adrenergic receptor binding in vivo with [18F]fluoroethyl-fenoterol in a guinea pig model (2005) (3)
Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD (2020) (3)
[Does phenotyping asthma help to improve differential treatment?]. (2010) (3)
Vitamin D insufficiency in adult asthma: Association with asthma severity and control (2012) (3)
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials (2016) (3)
Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma (2012) (3)
[Established combinations of inhaled corticoids and long-acting beta 2-symphathomimetics for long-term therapy of bronchial asthma. Position of an expert panel study]. (1999) (3)
[Measuring airway inflammation in clinical practise - application and interpretation]. (2007) (3)
Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma. (2021) (3)
Characteristics of Patients With and Without COPD Exacerbations During the Tiotropium + Olodaterol TONADO Studies (2016) (2)
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history (2019) (2)
COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study (2020) (2)
The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control. (2022) (2)
Inhaled Corticosteroid Plus Long-Acting Beta2-Agonist Therapy Is Overused In The Treatment Of Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analyses Of Two 1-Year Studies (2016) (2)
Allergen immunotherapy in the current COVID-19 pandemic - A position paper of the AeDA, ARIA, EAACI, DGAKI and GPA (2020) (2)
European Real-Life Experience Of Omalizumab (Xolair) And Maintenance Oral Corticosteroid Use In Patients With Severe Persistent Allergic Asthma (2009) (2)
The German severe asthma register (2012) (2)
No difference observed in the risk of malignancy in patients exposed to omalizumab compared with controls (2011) (2)
[efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases]. (2000) (2)
Effect of tiotropium/olodaterol combination therapy on long-term heart rate and blood pressure in COPD patients (2018) (2)
Statistical analysis of chronic obstructive pulmonary disease exacerbations in clinical studies: expectations and limitations. (2009) (2)
[Alfentanil as the last dose (on top) in neuroleptanesthesia with fentanyl. Pharmacokinetics and pharmacodynamics with reference to the cortical effect]. (1986) (2)
Budesonide/Formoterol Maintenance And Reliever Therapy At Two Different Maintenance Doses (2010) (2)
[Pathogenesis of idiopathic pulmonary fibrosis]. (1995) (2)
[Onset of action of formoterol in patients with moderate to severe, partially reversible airflow obstruction assessed by bodyplethysmography]. (2002) (2)
Tiotropium + Olodaterol Fixed-Dose Combination Therapy Provides Lung-Function Benefits Compared With Tiotropium Alone In Patients With GOLD A/B And C/D Chronic Obstructive Pulmonary Disease: Post Hoc Analyses Of Two 1-Year Studies (2016) (2)
Impact of donor lung quality on post-transplant recipient outcome in the LAS era in Eurotransplant. (2020) (2)
Patients with allergic and eosinophilic asthma in the German severe asthma registry (2015) (2)
Bronchodilator reversibility in the GAN severe asthma cohort. (2022) (2)
P260 Tiotropium Respimat® Add-on To Inhaled Corticosteroids Improves Lung Function In Patients With Symptomatic Mild Asthma: Results From A Phase Iii Trial (2014) (2)
COPD and the asthma-COPD-overlap-syndrome (2014) (2)
Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF): results from randomized clinical studies (2021) (2)
LUNG FUNCTION WITH TIOTROPIUM PLUS OLODATEROL IN EAST ASIAN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) (2015) (2)
[Immunomodulation therapy for allergic asthma. What is already possible, what is to come?]. (2008) (2)
A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol (2020) (2)
Impact of age, age at diagnosis and duration of asthma on the risk of exacerbations in the EuroSMART study (2012) (2)
Patient Baseline Characteristics Predict An Increased Risk Of Future Asthma Exacerbations (2010) (2)
[Early treatment of COPD with tiotropium]. (2012) (2)
Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort (2014) (2)
Free Serum IgE In Patients With Severe Allergic Asthma Treated With Omalizumab (2010) (2)
Global Initiative for Asthma Strategy 2021 (2022) (2)
Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies (2020) (2)
Efficacy of tiotropium/olodaterol compared with tiotropium in patients naive to LAMA, LABA and ICS: Pooled analysis of four clinical trials (2019) (2)
[Asthma: new insights and advances in treatment]. (2011) (2)
[Trial end-point in chronic obstructive pulmonary disease (COPD): minimal clinically important difference]. (2008) (2)
Efficacy of Once-Daily Tiotropium and Olodaterol Maintenance Treatment for COPD: Patient-Reported Outcomes (2015) (1)
Effect of Tiotropium + Olodaterol on the Use of Nighttime Rescue Medication in Patients With COPD: Results From Four Randomized, Double-Blind Studies (2015) (1)
[Strategies for gene therapy in cystic fibrosis]. (1996) (1)
[Management of acute exacerbation of chronic obstructive pulmonary disease (COPD)]. (2003) (1)
[Differential diagnosis of alveolitis in systemic diseases]. (1994) (1)
[Treatment strategies for asthma]. (2012) (1)
[Anticholinergic drugs in therapy of chronic obstructive lung disease (COPD)]. (2000) (1)
Lungenkarzinom (2008) (1)
[Oxidant-antioxidant imbalance in the experimental interstitial lung disease induced in sheep by visna-maedi virus]. (1997) (1)
Allergen Responses Modified by a GATA3 DNAzyme. (2015) (1)
Stepping Down from Triple Inhaled Therapy to a LABA/LAMA Fixed-Dose Combination: Data from the German Real-Life DACCORD COPD Cohort (2022) (1)
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma (2017) (1)
[Therapy of cystic fibrosis in adulthood--current and future management]. (1995) (1)
[Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease]. (2009) (1)
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study (2014) (1)
P46 Frequency of COPD exacerbations in the German DACCORD Registry (2015) (1)
The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting (2016) (1)
The Role of FeNO in Cough Management : A Randomised Controlled Trial (2018) (1)
[Waiting List Management and Organ Allocation for Lung Transplantation 2018]. (2019) (1)
Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials (2017) (1)
Low rate of exacerbations following initiation of LABA/LAMA fixed-dose combinations: An analysis of the DACCORD real life study (2017) (1)
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma (2011) (1)
P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B (2016) (1)
Symptom-guided adjustable dosing asthma therapy with budesonide and formoterol in a single inhaler—The ATACO study (2003) (1)
Correction to “ARIA guideline 2019: treatment of allergic rhinitis in the German health system” (2020) (1)
[Hemorrhagic pericardial effusion and multiple pulmonary nodules in a 37 year old male who has "never smoked"]. (2009) (1)
Unspecific bronchial reactivity to carbachol in healthy subjects--effect of age and smoking habits. (1994) (1)
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update (2023) (1)
Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lung Allocation for Precarious Patients. (2020) (1)
Tiotropium Plus Olodaterol Fixed-Dose Combination Therapy Provides Lung Function Benefits When Compared With Tiotropium Alone, Irrespective Of Prior Treatment With A Long-Acting Bronchodilator: Post Hoc Analyses Of Two 1-Year-Studies (2016) (1)
[Inhalable corticosteroids in long-term COPD treatment. Opinions of an expert panel]. (2000) (1)
Fractional exhaled nitric oxide is associated with more severe asthma (2018) (1)
Tolérance du tiotropium Respimat en traitement additionnel d’un traitement continu par CSI ± LABA chez des patients adultes ayant un asthme symptomatique : analyse des données groupées (2015) (1)
[Clinical trial endpoints in alpha-1-antitrypsin deficiency: interdisciplinary aspects]. (2011) (1)
[Chronic obstructive pulmonary disease: the right treatment for the right patient]. (2021) (1)
[Treatment of COVID-19 with Inhaled Glucocorticoids - Statement of the German Respiratory Society (DGP), the Austrian Society of Pneumology (ÖGP) and the German Society of Allergology and Clinical Immunology (DGAKI)]. (2021) (1)
[Bronchodilators in chronic obstructive pulmonary disease (COPD)]. (2005) (1)
P285 The ‘real-life’ copd patient in the age of laba/lamas: an expansion of the daccord study (2016) (1)
Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study (2022) (1)
Effects of 5 mg sublingual nitrendipine in patients with precapillary pulmonary hypertension due to pulmonary fibrosis. (1988) (1)
[Correlation of plasma glutathione and total IgE level: evidence for a regulatory role of antipxodants in vivo]. (2000) (1)
Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea (2012) (1)
Hepatopulmonary syndrome (HPS) in chronic viral hepatitis (1998) (1)
Short-Term Reproducibility Of Non-Invasive Clinical And Inflammatory Parameters In Asthma (2011) (1)
[Immunopathogenesis of extrinsic allergic alveolitis]. (1995) (1)
Clinically meaningful FEV1 response with reslizumab achieved early and sustained over 52 weeks (2017) (1)
Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis (2022) (1)
Characterising individual response to mepolizumab treatment (2020) (1)
[National Disease Management Guideline for Asthma: recommendations and evidence for "asthma prevention" issues]. (2006) (1)
Viral Components Enhance Antigen Presentation And Induce Sensitization Towards Harmless Inhaled Antigens (2010) (0)
Compared with Th2 Th1-Induced Airway Inflammation Regulatory T Cells More Effectively Suppress (2011) (0)
Small airway disease (SAD) is associated with respiratory symptoms and relevant for therapy in early COPD (2020) (0)
EVS2-3 New treatment approach to severe allergic asthma (2007) (0)
The role of IL-22 in allergic airway disease (2011) (0)
[Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma]. (2010) (0)
TS5-5 Asthma Therapy : The Day After Tomorrow (2010) (0)
Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Previous Usage Of Inhaled Corticosteroids (2016) (0)
[Clinical aspects and diagnosis of chronic berylliosis--a case report]. (1990) (0)
Reply to the Letter Entitled “FeNO Variability when Using Different Analyzers at the Joint ATS/ERS Guideline Cutoff” (2019) (0)
Long-Term Safety of Tiotropium/Olodaterol Respimat in Elderly Patients with Moderate to Very Severe COPD in the TONADO Studies (2018) (0)
Cytokine Production Profile Of T-lymphocytes In Patients With Allergic Asthma Receiving Anti-IgE Therapy (2010) (0)
Efficacy of Once-Daily Tiotropium Respimat ® on Lung Function and Asthma Control in Adults with Asthma at GINA Steps 2–5 (2018) (0)
Disease Progression in COPD Patients Classified as Gold D According to Gold 2011 or Gold 2017 in the Real-Life Daccord Study (2019) (0)
Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study (2018) (0)
Is inhaler technique adequately assessed and reported in clinical trials of asthma and COPD therapy? A systematic review and suggested best practice checklist. (2022) (0)
Cytokine production profile of T-lymphocytes and frequence of regulatory T-cells in patients with allergic asthma receiving anti-IgE therapy (2011) (0)
[Lung cancer]. (2008) (0)
2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the 'real-life' DACCORD study (2016) (0)
Tiotropium Early Treatment of COPD with Tiotropium (2012) (0)
THE INHIBITORY EFFECT OF THE PLANT KALANCHOE PINNATA AND ITS FLAVONOID QUERCETIN ON AIRWAY HYPERRESPOSIVENESS (2010) (0)
Recommendations for use of topical inhalant budesonide in COVID-19 (2021) (0)
Acknowledgement to reviewers 2009 (2009) (0)
Therapie mit Anti-Interleukin-5 bei Patienten mit hypereosinophilem Asthma (2007) (0)
Omalizumab decreases IgE production in patients with severe allergic asthma (2012) (0)
['95 pneumology update. Progress and perspectives in pneumology. Paradigms of change (II)]. (1995) (0)
GARP reduces inflammation in a humanized mouse model of allergic airway disease (2015) (0)
Late Breaking Abstract - Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial (2017) (0)
Dual bronchodilation vs triple therapy in the real-life DACCORD study (2018) (0)
AAAAI ARIETTA study design poster for DGP (2016) (0)
EVS5-3 Global strategies of asthma treatment (2012) (0)
Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the United States (2022) (0)
Glutathione in spennatozoa and seminal plasn1a infertile men (2011) (0)
A New Dosimeter Methacholine Challenge Protocol Based On A Single Methacholine Concentration (2010) (0)
Type 2 biomarker expression according to age of asthma onset: an analysis of the German severe asthma registry (GAN) (2022) (0)
Anti-IgE Therapy for Asthma (2005) (0)
Gp120 reduces AHR and airway inflammation in a humanized mouse model of allergic asthma through activation of regulatory T cells (2011) (0)
Prospective evaluation of asthma control using three different classification systems (2011) (0)
[Guidelines for diagnosis and therapy of patients with asthma 2005. The most important aspects for adults]. (2006) (0)
[Pathogenesis of bronchial asthma--unveiling new therapeutic prospects]. (2001) (0)
Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry (2014) (0)
[Do fixed ICS/LABA-combinations have advantages in terms of patient-centered parameters?]. (2009) (0)
[Antioxidants in therapy of lung diseases. Concepts and reality]. (1996) (0)
Individual and Synergistic Effects of IL-5 and IL-13 on Trans-Compartmental Activation and Migration of Eosinophils and Murine Asthma Features (2016) (0)
Inhibition of cAMP Degradation Improves Regulatory T Cell-Mediated Suppression of Allergic Airway Disease. (2009) (0)
Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort (2020) (0)
The German Severe Asthma Registry and Type 2-high and Type 2-low asthma phenotypes (2019) (0)
PRS11 COST-EFFECTIVENESS OF INCREASING MAINTENANCE DOSES WITH BUDESONIDE/FORMOTEROL MAINTENANCE + RELIEVER THERAPY (2008) (0)
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma (2019) (0)
Synergistic effect of disodium cromoglycate and reproterol in preventing exercise-induced asthma (EIA) in adults (2010) (0)
Cytomegalovirus (CMV) modulates the immune responses against inhaled harmless antigens (2015) (0)
Adenovirus-mediated interferon-β gene therapy combined with radiotherapy synergistically inhibits lung tumor growth in mice (2004) (0)
inflammatory cell-derived oxidants in cystic fibrosis Glutathione aerosol suppresses lung epithelial surface (2015) (0)
15. Mainzer Allergie-Workshop 2003 (2003) (0)
Change of COPD maintenance medication over two years in a large real life cohort: The DACCORD study (2016) (0)
Airflow limitation and hyperinflation Dyspnoea Reduced physical activity and exercise capacity Impaired health status Disease progression Mortality (2010) (0)
New fixed bronchodilator combinations of a long-acting β2-agonist and a long-acting anticholinergic (2012) (0)
Bcl-2, Bcl-xl, and pp32/PHAPI in Resected Non-Small-Cell Lung Cancer Patients. (2009) (0)
What are common COPD symptoms in a real-life setting? The German DACCORD registry (2014) (0)
[COVID-19 Vaccination in Asthma Patients Treated with Biologicals - Statement of the Austrian Society of Pneumology and German Respiratory Society]. (2021) (0)
[Solid combination of budesonide and formoterol in the treatment of bronchial asthma]. (2001) (0)
Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement (2013) (0)
Lung function in idiopathic pulmonary fibrosis - explorative analyses of the IFIGENIA trial (2009) (0)
Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease (2015) (0)
P141 2-year follow-up of COPD patients in the non-interventional ‘real-life’ daccord study in germany (2016) (0)
Development and Validation of an Electronic Daily Control Score for Asthma (e-DASTHMA) (2022) (0)
The Severe Asthma Registry – German data (2018) (0)
P121 Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO (2015) (0)
Cardio- and Cerebrovascular Safety of Qva149 in Patients with Moderate to Severe Copd: A Pooled Analysis (2015) (0)
Corrigendum to “The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update” [Respiratory Medicine 103 (2009) 1098–1113] (2010) (0)
ResearchArticle Soluble Triggering Receptor Expressed on Myeloid Cells 1 Is Released in Patients with Stable Chronic Obstructive Pulmonary Disease (2007) (0)
Der Wnt/β-Catenin Signalweg beeinflusst DC/T Zell Interaktionen in vitro (2014) (0)
Measurement of exhaled nitric oxide: comparison of 3 different analyzers (2018) (0)
Classification of small cell lung cancer (SCLC): IASLC or VALG - beyond the limits of limited disease (2000) (0)
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma (2015) (0)
[Modern management of asthma]. (2009) (0)
[Gene therapy in cancers of the lung and pleura]. (1999) (0)
Th1-induced Allergic Airway Disease Is More Susceptible To NTreg-mediated Suppression In Contrast ToTh2 Responses (2010) (0)
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum] (2014) (0)
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study (2015) (0)
Protective Effect Of Disodium Cromoglycate In Exercise-induced Asthma In Adults And Its Synergistic Effect In A Fixed Drug Combination With Reproterol (2010) (0)
Analysis Of Pulmonary Inflammation Using Humanized Mouse Models (2010) (0)
CAPTAIN: Improvements in airflow obstruction in patients with uncontrolled asthma (2021) (0)
[Difficult to manage asthma: clinical phenotypes and principles of therapy]. (2002) (0)
Short-term and long-term reproducibility of non-invasive clinical and inflammatory parameters in asthma (2012) (0)
Allergic Sensitization to Inhaled Allergen TLR3 but Not TLR7/8 Ligand Induces (2012) (0)
[Effectiveness and tolerance of a combination of fluticasone and salmeterol in patients with obstructive airway diseases. DUO Study Group]. (1998) (0)
[Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD)]. (2003) (0)
Treatment with Tiotropium plus Olodaterol Respimat improves physical functioning of COPD patients in a real life setting (2016) (0)
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials (2019) (0)
The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort (2022) (0)
Low-dose CT als gute Alternative zur Darstellung des ventrikuloperitonealen Shuntverlaufs bei Erwachsenen // Low-dose CT as Reliable Alternative for Imaging Ventriculoperitoneal Shunts in Adults (2016) (0)
Similar Camp Transfer Of Naturally Occurring Regulatory T Cells More Effectively Suppresses Effector Functions Of Th1 Compared To Th2 Cells (2011) (0)
The Fevipiprant Phase IIIb Systemic Corticosteroid Avoidance Study: SHIELD (2019) (0)
Analysis of Rescue Medication Use over 1 Year in Patients Receiving LAMA, LABA, or Combination Maintenance Treatment for COPD in the TONADO Studies (2017) (0)
A short splice variant of the tumor suppressor gene CYLD induces allergic airway disease in mice and is also expressed in humans (2015) (0)
75 Allergen cross-reactivity between α-amylase (aspergillus oryzae), hemicellulase (A. niger) and amyloglycosidase (A. niger) (1996) (0)
Exposure to Toll like Receptor 7 (TLR7)-Ligand Supports Sensitization to an Inhaled Allergen. (2009) (0)
The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany (2013) (0)
EXPRESSION OF T-CELL TRANSCRIPTION FACTOR T-BET IS INCREASED IN COPD (2010) (0)
T cell specific expression of a short splice variant of the tumor suppressor gene CYLD amplifies the development of allergic airway disease (2011) (0)
The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials (2017) (0)
Comparison of initial drug treatment of incident COPD patients with German treatment guidelines (2021) (0)
The German Severe Asthma Registry: FeNO values correlate with medical therapy, quality of life and smoking (2019) (0)
Quantification Of Total Serum IgE In Patients With Asthma Using 3 Different Methods (2010) (0)
[Cost effectiveness of BDP/formoterol fixed vs. two single inhalers in the treatment of bronchial asthma]. (2010) (0)
[Paraneoplastic limbic encephalitis in small cell lung carcinoma]. (2004) (0)
[Therapy of lung cancer]. (2005) (0)
Akute eosinophile Pneumonie als Differenzialdiagnose der Antibiotika-resistenten Pneumonie (2004) (0)
['95 pneumology update. Progress and prospects in pneumology. Paradigm of change--II]. (1996) (0)
Contribution of glutathione to the antioxidant defenses of the respiratory tract (1997) (0)
Demonstration of pulmonary beta2-adrenergic receptor binding in vivo with [18F]fluoroethyl-fenoterol in a guinea pig model. (2005) (0)
Determining SGRQ and TDI responder rates across the duration of clinical trials: Results from tiotropium + olodaterol in COPD (2017) (0)
[Clinical significance of gastrooesophageal reflux in asthma]. (2006) (0)
Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease (2013) (0)
Budesonide/Formoterol Maintenance And Reliever Therapy In Patients With Difficult-To-Control Asthma (2011) (0)
Subject Index Vol. 25, 2004 (2004) (0)
Anti-type2-Antibodies Specifically Inhibit Murine Asthma Features Induced By Intranasal Application of IL-5 and IL-13 (2016) (0)
Use of biologics in allergic and type 2 inflammatory diseases in the current Covid 19 pandemic(a, b, c) (2020) (0)
A Guideline-based Survey Of COPD Management Of Pneumologists In Germany (2010) (0)
In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations (2023) (0)
Smoking status and its impact on COPD: an analysis of the observational DACCORD study (2019) (0)
The German Severe Asthma Registry: Obesity is associated with asthma parameters (2020) (0)
[Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. (2002) (0)
Budesonide/Formoterol Maintenance And Reliever Therapy At Two Different Maintenance Doses: Effect On Fractional Excretion Of Nitric Oxide (FENO) (2010) (0)
FeNO as predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility; a randomised controlled trial (2017) (0)
EVELUT®: dyspnoea and symptom burden in COPD patients switching from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS (2022) (0)
Late-breaking abstract: Attenuation of allergen-induced asthmatic responses by inhaled GATA-3 specific DNAzyme (2014) (0)
Corrigendum to "The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control" [Respir. Med. 195 (2022) 106793]. (2022) (0)
Contents Vol. 25, 2004 (2004) (0)
[Guideline-adherent treatment for asthma]. (2008) (0)
Prevention Of COPD Exacerbations With Tiotropium Versus Salmeterol: Pooled Analysis From Clinical Studies (2011) (0)
[Treatment of small airway diseases--today and tomorrow]. (2009) (0)
The frequent exacerbator in real-life: an analysis of the DACCORD study (2019) (0)
Analysis of the frequency of COPD exacerbations in the 'real-life' DACCORD study over a 2 year period (2016) (0)
COPD in elderly patients – an analysis of the DACCORD observational study (2018) (0)
IL5 and IL13 modulate trans-compartmental activation and migration of eosinophils (2015) (0)
Corrigendum to "Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma" [Pulm. Pharmacol. Therapeut. 70 (2021) 102068]. (2022) (0)
P-133 Synergy of radiotherapy and adenovirus mediated interleukin 12 gene therapy in the treatment of mouse lung tumors (2005) (0)
Immunologie I (2011) (0)
Subject Index Vol. 28, 2007 (2008) (0)
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial (2011) (0)
Bcl-2, Bcl-xl, and pp32/PHAPI in resected non-small-cell lung cancer patients (2009) (0)
Reduction Of Pulmonary Inflammation Through HIV-1 Envelope Protein GP120 In A Humanized Mouse Model Of Allergic Asthma Depends On Regulatory T Cells (2011) (0)
Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Initial Disease Severity (2016) (0)
ES17-2 Novel treatments of asthma (2012) (0)
EVS1-3 New treatment approach to severe allergic asthma : Real life study in Germany (2010) (0)
Comparison of Exhaled Nitric Oxide (eNO) Measurements with 5 Different Analyzers. (2009) (0)
COPD_A_195852 1441..1453 (2019) (0)
AB040. Determinants of increase FeNO in individuals with suspected asthma (2016) (0)
Author Correction (2015) (0)
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers (2015) (0)
[Antioxidative treatment of idiopathic pulmonary fibrosis]. (2006) (0)
Lithium Chloride Affects The Development Of Allergic Airway Disease (2012) (0)
[The path from the pediatrician to the internist]. (1996) (0)
Delivery of parenteral nutrition by `all in one bag' (AIO) versus single bottle system (SBS) in critically ill patients: a prospective randomized trial (2000) (0)
[beta(2)-Sympathomimetics: risks for asthma therapy? Lessons from the SMART1 Study. A statement from the German Respiratory Tract League]. (2007) (0)
Drug treatment in a German real-life COPD cohort (DACCORD) (2015) (0)
Combined tiotropium + olodaterol influences physical functioning in COPD: Results of an open-label observational study (2016) (0)
Expression of Th1, Th2 and Th17 cytokines in CD4+ T cells in peripheral blood of asthma patients (2014) (0)
P120 Real life distribution of COPD severity in the German DACCORD registry: Lung function is the main driver of classification in GOLD group C and D (2015) (0)
[COPD, a systemic disease--nutritional approaches]. (2004) (0)
Time to COPD Exacerbation in the TONADO Studies by Disease Severity (Global Initiative for Chronic Obstructive Lung Disease [GOLD]) and Baseline Inhaled Corticosteroid (ICS) Use (2016) (0)
Adenovirus-mediated interferon-β gene therapy combined with radiotherapy synergistically inhibits lung tumor growth in mice. (2004) (0)
[Recommendations for use of topical inhalant budesonide in COVID-19 : A position paper of the German Society for Applied Allergology (AeDA) and the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO). German version]. (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roland Otto Buhl?

Roland Otto Buhl is affiliated with the following schools:

Roland Otto Buhl's Academic­Influence.com Rankings

Roland Otto Buhl's Degrees

Why Is Roland Otto Buhl Influential?

Roland Otto Buhl's Published Works

Published Works

What Schools Are Affiliated With Roland Otto Buhl?

Roland Otto Buhl's AcademicInfluence.com Rankings